Metastatic melanoma burden in the lungs was significantly reduced by anti‐PD‐1 and anti‐CTLA‐4 treatment, which was comparable to the protection afforded by HPK1 deficiency alone (Figure 5g,h). This evidence concerns the gene MAP4K1 and melanoma.